A clinical trial of omadacycline found the drug was as effective at treating community-acquired pneumonia as moxifloxacin.
In the OPTIC (Omadacycline for Pneumonia Treatment in the Community) trial, patients were randomly assigned, on a 1:1 basis, to receive IV omadacycline or IV moxifloxacin for 7 to 14 days, with a transition to oral versions of the two drugs allowed after 3 days.
Of the 774 patients, 386 received omadacycline and 388 received moxifloxacin. The results showed that 81.1% of patients in the omadacycline arm had an early clinical response, compared with 82.7% of patients in the moxifloxacin arm, demonstrating noninferiority. The rates of investigator-assessed clinical response at 5 to 10 days post-treatment were 87.6% for omadacycline and 85.1% for moxifloxacin.
